Short Interest in Gossamer Bio, Inc. (NASDAQ:GOSS) Expands By 10.0%

Gossamer Bio, Inc. (NASDAQ:GOSS) was the target of a significant increase in short interest in December. As of December 15th, there was short interest totalling 7,020,000 shares, an increase of 10.0% from the November 30th total of 6,380,000 shares. Based on an average daily trading volume, of 1,290,000 shares, the days-to-cover ratio is presently 5.4 days.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in GOSS. TD Asset Management Inc lifted its holdings in Gossamer Bio by 51.9% during the 2nd quarter. TD Asset Management Inc now owns 641,498 shares of the company’s stock valued at $578,000 after purchasing an additional 219,238 shares during the last quarter. Acadian Asset Management LLC lifted its position in Gossamer Bio by 31.3% during the 2nd quarter. Acadian Asset Management LLC now owns 3,592,765 shares of the company’s stock worth $3,235,000 after buying an additional 856,380 shares in the last quarter. Choreo LLC acquired a new stake in Gossamer Bio in the 2nd quarter valued at about $46,000. Monaco Asset Management SAM increased its holdings in shares of Gossamer Bio by 390.3% in the second quarter. Monaco Asset Management SAM now owns 2,726,104 shares of the company’s stock valued at $2,456,000 after purchasing an additional 2,170,104 shares in the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of Gossamer Bio by 204.7% during the second quarter. Renaissance Technologies LLC now owns 2,046,600 shares of the company’s stock worth $1,844,000 after acquiring an additional 1,375,000 shares during the last quarter. 81.23% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Gossamer Bio in a report on Monday, November 11th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Gossamer Bio has a consensus rating of “Buy” and an average target price of $9.20.

Gossamer Bio Price Performance

NASDAQ:GOSS opened at $0.90 on Thursday. Gossamer Bio has a 52 week low of $0.50 and a 52 week high of $1.60. The company has a debt-to-equity ratio of 3.64, a quick ratio of 6.74 and a current ratio of 6.74. The company has a market capitalization of $204.99 million, a price-to-earnings ratio of -2.83 and a beta of 1.85. The company has a 50-day moving average of $0.81 and a 200-day moving average of $0.90.

Gossamer Bio (NASDAQ:GOSS) last issued its earnings results on Thursday, November 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04. The company had revenue of $9.48 million during the quarter, compared to analyst estimates of $4.52 million. As a group, equities research analysts anticipate that Gossamer Bio will post -0.28 earnings per share for the current fiscal year.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.